国金证券股份有限公司 关于上海润达医疗科技股份有限公司 不提前赎回"润达转债"的核查意见 国金证券股份有限公司（以下简称"本保荐机构"）作为上海润达医疗科技 股份有限公司（以下简称"润达医疗"、"公司"）公开发行可转换公司债券的 保荐机构，根据《证券发行上市保荐业务管理办法》、《上海证券交易所上市公 司自律监管指引第12号——可转换公司债券》等相关规定，对润达医疗不提前赎 回"润达转债"事项进行了认真、审慎的核查。核查的具体情况如下： 一、可转债发行上市基本情况 （一）经中国证券监督管理委员会证监许可[2020]586 号文核准，上海润达 医疗科技股份有限公司于 2020 年 6 月 17 日公开发行了 5,500,000 张（550,000 手）可转换公司债券，每张面值 100 元，发行总额 55,000 万元，发行期限 6 年， 票面利率分别为：第一年 0.3%、第二年 0.6%、第三年 1.0%、第四年 1.5%、第 五年 1.8%、第六年 2.0%。 （二）经上海证券交易所"[2020]185 号"自律监管决定书同意，公司 55,000 万元可转换公司债券于 2020 年 7 月 13 日起在上海证券 ...

Core Viewpoint - Shanghai RunDa Medical Technology Co., Ltd. is facing challenges in revenue and profit due to macroeconomic conditions and policy impacts, but is focusing on innovation and AI integration to drive future growth [4][5][6]. Financial Performance - The company achieved operating revenue of 8.312 billion yuan, a decrease of 9.13% year-on-year [4]. - The net profit attributable to shareholders was 55 million yuan, down 79.77% compared to the previous year [4]. Business Strategy - The company is implementing a dual-driven strategy of "stabilizing the foundation and seeking innovation" to enhance its core service and self-produced product businesses [5]. - It is increasing investments in AI medical applications and deepening technological innovation and industrial collaboration [5][9]. Market Position - The company has a total of 432 centralized and regional testing center clients, an increase of 23 clients compared to the previous year [6]. - It is actively expanding into the upstream IVD manufacturing sector and has launched several new products, maintaining a leading position in the domestic market for glycosylated hemoglobin testing [8]. AI Integration - The company is leveraging its expertise in the medical vertical to develop AI solutions, collaborating with over 80 hospitals to provide digital solutions [9][10]. - It has launched the "HuaQing ZhiYi" training and deployment machine, offering comprehensive AI solutions for medical institutions [10]. Corporate Governance - The board of directors held nine meetings in 2024, discussing various proposals including credit limits and executive compensation [12]. - The supervisory board conducted six meetings, reviewing the company's financial status and compliance with regulations [18][19]. Shareholder Engagement - The company is committed to maintaining effective communication with shareholders, ensuring transparency in decision-making processes [22][35]. - It has implemented a cash dividend policy, distributing 1 yuan per 10 shares to shareholders based on its financial health and future growth prospects [29].

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-022 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、可转债发行上市概况 （一）经中国证券监督管理委员会证监许可[2020]586 号文核准，上海润达 医疗科技股份有限公司（以下简称"公司"）于 2020 年 6 月 17 日公开发行了 5,500,000 张（550,000 手）可转换公司债券，每张面值 100 元，发行总额 55,000 万元，发行期限 6 年，票面利率分别为：第一年 0.3%、第二年 0.6%、第三年 1.0%、 第四年 1.5%、第五年 1.8%、第六年 2.0%。 （二）经上海证券交易所"[2020]185 号"自律监管决定书同意，公司 55,000 万元可转换公司债券于 2020 年 7 月 13 日起在上海证券交易所上市交易，债券简 称"润达转债"，债券代码"113588"。 （三）根据有关 ...

上海润达医疗科技股份有限公司 2024 年年度股东大会 会 议 材 料 【二零二五年五月】 上海润达医疗科技股份有限公司 资料目录 | 一、2024年年度股东大会议程--------------------------------------------1 | | | --- | --- | | 二、会议注意事项----------------------------------------------------------------------3 | | | 三、审议事项 | | | 议案一：2024 | 1. 年度董事会工作报告-----------------------------------------4 | | 议案二：2024 | 2. 年度监事会工作报告----------------------------------------12 | | 议案三：2024 | 3. 年度独立董事述职报告------------------------------------16 | | 议案四：2024 | 4. 年度财务决算报告----------------------------------- ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2]. Core Insights - The report highlights a significant rebound in the stock prices of leading US healthcare AI companies, with Tempus and Grail both experiencing a 65% increase over the past month. This sector is noted for its rapid implementation and growing investor interest [8][10]. - It suggests focusing on domestic companies that can mirror the growth of these US AI leaders, particularly those like RunDa Medical and YiMaiTong, which are positioned to leverage AI for substantial performance gains [10][12]. Summary by Sections 1. Focus on US AI Leaders and Domestic Opportunities - The report emphasizes the recent stock price rebounds of US healthcare AI leaders, with notable increases of 65% for Tempus and Grail, and suggests that AI in healthcare is one of the fastest-growing fields [8]. - It recommends monitoring domestic companies such as RunDa Medical and YiMaiTong for potential investment opportunities as they implement AI solutions [10][12]. 2. Weekly Market Review and Hotspot Tracking (May 6 - May 9, 2025) - The report notes that the Shenwan Pharmaceutical and Biotechnology Index rose by 1.01% during the week, underperforming the CSI 300 Index by 1.0%. Year-to-date, the index has increased by 1.19%, outperforming the CSI 300 by 3.44% [32]. - The top-performing stocks during this period included Changshan Pharmaceutical (up 23.59%) and Xiangxue Pharmaceutical (up 19.64%) [44]. 3. Company Highlights - RunDa Medical has established deep collaborations with Huawei to implement AI solutions across over 80 hospitals, enhancing its digital healthcare offerings [12][13]. - YiMaiTong, a leading online professional physician platform in China, has seen its registered physician count grow to over 4 million, with a compound annual growth rate (CAGR) of 24.9% in paid clicks from 2018 to 2024 [17][20]. 4. Monthly Investment Portfolio - The report lists a monthly investment portfolio that includes companies such as Kangfang Biotech, Zai Lab, and Titan Technologies, indicating a focus on firms with strong fundamentals and growth potential [5].

Core Viewpoint - The IVD industry is experiencing a significant downturn in revenue and profits, with over 70% of companies reporting a year-on-year decline in revenue and more than half facing losses or drastically reduced profits [2][5]. Revenue and Profit Trends - In Q1 2025, major IVD companies such as Mindray Medical, Dian Diagnostics, and RunDa Medical reported substantial declines in both revenue and net profit, with Mindray's revenue at 8.237 billion yuan (down 12.12%) and net profit at 2.629 billion yuan (down 16.81%) [2][4]. - Among 60 IVD companies analyzed, 16 reported revenue growth, with 8 achieving both revenue and net profit growth [2]. Market Challenges - The IVD sector is facing multiple challenges, including a slowdown in the conventional medical testing market, stricter cost control policies in healthcare, and the impact of centralized procurement policies [5][6]. - The anticipated centralized procurement in 28 provinces is expected to further pressure IVD companies, particularly in the high-volume chemical luminescence market [6]. Company Strategies and Innovations - Some companies are adapting by focusing on niche markets and innovative product offerings, such as New Industry and Sansure Bio, which reported revenue growth of 10.12% and 21.62% respectively in Q1 2025 [9]. - Companies are also exploring international markets, with Mindray's overseas revenue reaching 16.43 billion yuan in 2024, accounting for 44.75% of total revenue [9][10]. Technological Advancements - The IVD industry is witnessing a shift towards digitalization and AI integration, with partnerships like that of BGI and Dian Diagnostics aiming to enhance diagnostic efficiency and precision [10][11]. - The emergence of AI technologies is reshaping the IVD landscape, although challenges remain in data integration and commercialization [11].

A股医药商业板块异动拉升，嘉事堂封板涨停，瑞康医药、润达医疗、漱玉平民、合富中国、海王生物 等跟涨。 ...

| 601688 | 华泰证 | 5 | 2.08 | 6.01 | 1.76 | | --- | --- | --- | --- | --- | --- | | | 券 | | | | | | 603005 | 晶方科 | 5 | 1.94 | 5.46 | 9.07 | | | 技 | | | | | | 000933 | 神火股 | 7 | 1.91 | 6.53 | 4.81 | | | 份 | | | | | | 300657 | 弘信电 | 5 | 1.79 | 4.55 | 11.37 | | | 子 | | | | | | 688158 | 优刻得 | 5 | 1.78 | 5.36 | 13.31 | | 000630 | 铜陵有 | 5 | 1.71 | 8.40 | 1.58 | | | 色 | | | | | | 300382 | 斯莱克 | 5 | 1.62 | 8.36 | 24.17 | | 688208 | 道通科 | 5 | 1.50 | 5.56 | 14.00 | | | 技 | | | | | | 002558 | 巨人网 | 5 | 1.37 | 5.25 | 11. ...

关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-021 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 一、担保情况概述 重要内容提示： （一）为支持上海润达医疗科技股份有限公司（以下简称"公司"）全 资及控股子公司的发展，解决其流动资金短缺问题，经公司董事会及 2023 年度股东大会审议通过：自 2024 年 5 月 23 日至 2024 年度股东大会召开之 日期间，为公司全资及控股子公司向（类）金融机构申请总额不超过人民币 421,300 万元的授信额度提供连带责任保证担保，控股子公司其他股东提供 对等担保或为公司提供足额反担保，公司实际承担出资比例对应的担保金额。 被担保人名称：三家全资子公司：杭州润达、惠中生物、哈尔滨润达； 五家控股子公司：合肥润达、云南康泰、武汉尚检、合肥三立、润达榕 嘉。被担保人非上市公司关联人。 ...

Core Viewpoint - The A-share smart medical sector experienced significant upward movement in the afternoon, with several companies reaching their daily limit up [1] Company Performance - Saily Medical and Runda Medical both hit the daily limit up, indicating strong investor interest and positive market sentiment [1] - Hongbo Co., Ltd. previously reached the daily limit up, showcasing a trend of rising stock prices within the sector [1] - Hongjing Technology, Chuangye Huikang, and Taikang Medical all saw their stock prices increase by over 8%, further highlighting the sector's robust performance [1]